CD86 and neoplasm: The immunotherapeutic antibodies directed against these immune checkpoint molecules, such as nivolumab, ipilimumab, and pembrolizumab, reactivate the cytotoxic T cells to eradicate tumor cells via blocking the PD-L1/PD-1 or CTLA-4-CD80/CD86 signaling pathways [3].